Target Market.
By 2040, there will be
over 700 million people
with diabetes
100% of patients with Type 1 diabetes
>60% of patients with Type 2 diabetes
will develop diabetic retinopathy (DR)
GO -TO -MARKET Strategy
Patenting
-
Two patent families with strong claims covering key markets: US, Canada, EU, China, etc.
-
Patent family 1: WO2022006667
-
Priority: July 2020
-
In national phase
-
-
Patent family 2: WO2025175400
-
Priority: Feb 2024
-
PCT Published
-
Development
-
DR2 preclinical development through phase I
-
Partnering for phase II/phase III
-
Ongoing engagement with industry, clinical stakeholders to prepare for IND and phase 1
Regulatory Affair
-
Devising strategy with reference to existing siRNA therapeutics on the market for other condition
-
Engaging regulatory bodies early and regularly
-
Partnering with regulatory consultants in key markets
Financing
-
Pursuing diversified funding (grants, F&F, non-dilutable)
-
Innovation & grant ecosystem engagement
-
Milestone-based fundraising